Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

OPGEN INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)

02/28/2020 | 05:14pm EST

Item 1.01 Entry into a Material Definitive Agreement.

As previously disclosed, on September 4, 2019, OpGen, Inc. (the "Company") entered into a business combination transaction pursuant to an Implementation Agreement (the "Implementation Agreement"), by and among the Company, Curetis N.V., a public company with limited liability under the Laws of the Netherlands ("Curetis"), and Crystal GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany and wholly owned subsidiary of the Company (the "Purchaser"). Under the Implementation Agreement, the Company agreed to assume, as a condition to closing the transactions under the Implementation Agreement, all of the outstanding convertible notes (the "Convertible Notes") issued by Curetis in favor of YA II PN, LTD ("Yorkville"), pursuant to that certain Agreement for the Issuance of and Subscription to Notes Convertible into Shares and Share Subscription Warrants, dated October 2, 2018, by and between Curetis and Yorkville.

On February 24, 2020, the Company entered into an Assignment of the Agreement for the Issuance of and Subscription to Notes Convertible into Shares (the "Assignment Agreement") with Curetis and Yorkville. The Assignment Agreement satisfies the Company's condition to closing of assuming the Convertible Notes and provides that, effective as of the closing of the transactions contemplated by the Implementation Agreement, the Company will assume all of the outstanding Convertible Notes. In addition, pursuant to the Assignment Agreement, upon assumption of the Convertible Notes by the Company, the Convertible Notes will cease to be convertible into shares of Curetis and will instead be convertible into shares of the Company's common stock, par value $0.01. The Assignment Agreement provides that an amount of 500,000 shares of the Company's common stock that comprise a portion of the consideration payable by the Company under the Implementation Agreement will be reserved for issuance under the Convertible Notes. The Company also agreed to register for resale up to 1,000,000 shares of Company common stock issuable upon conversion of the Convertible Notes within the later of 60 days following the later of the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2019 and the closing of the transactions contemplated by the Implementation Agreement.

Each Convertible Note has a maturity of 12 months from its date of issuance. Curetis, or after closing of the transaction contemplated by the Implementation Agreement, the Company, has the right to extend such maturity by an additional 12-month period, while paying a cash fee equal to 5% of the principal amount of the relevant Convertible Notes. Subject to certain limitations, the maturity period can be extended up to four times.

The Convertible Notes shall not accrue interest, except in the case of an event of default under the Convertible Notes, in which case the Convertible Notes shall accrue default interest at a rate of 15% per annum until the earlier of the date that the event of default is cured or the date on which the Convertible Notes have been fully converted or redeemed.

The Convertible Notes may be converted at any time until they are fully redeemed. Upon conversion of one or more Convertible Notes into shares of the Company's common stock, the number of Company shares will be calculated by dividing the aggregate principal amount of the relevant Convertible Notes by 93% of the lowest daily volume weighted average price of the Company common stock on the Nasdaq Capital Market over the 10 trading days prior to the conversion date.

The Convertible Notes may be freely transferred, except to retail investors, and subject to compliance with applicable securities laws. The Convertible Notes contain anti-dilution protection, which protects the holder of the security from equity dilution resulting from later issues of shares at a lower price or value than that provided for in the security. The protection in the Convertible Notes takes the form of tying the conversion price of the Convertible Notes to the prevailing market price of the underlying shares of Company common stock so that changes to the share price due to share issuances, share splits or other potentially dilutive events will result in a corresponding change in the number of shares of Company common stock issuable upon conversion of a Convertible Note.

As of February 24, 2020, an aggregate amount of €1.3 million of unconverted Convertible Notes was outstanding.

The foregoing description of the Assignment Agreement is only a summary and is qualified in its entirety by reference to the complete text of the Assignment Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.          Document
10.1          Assignment of the Agreement for the Issuance of and Subscription to
            Notes Convertible into Shares, dated February 24, 2020, among OpGen,
            Inc., YA II PN, LTD, and Curetis N.V.

© Edgar Online, source Glimpses

All news about OPGEN, INC.
11/24OPGEN INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equ..
AQ
11/24OPGEN : Announces $10 Million Private Placement Priced at the Market
AQ
11/24OpGen, Inc. Announces $10 Million Private Placement Priced at the Market
GL
11/16OPGEN : Note 2 - Liquidity and management's plans
AQ
11/13OPGEN : Corporate Presentation (PDF)
PU
11/13OPGEN INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
AQ
11/12OPGEN : Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Test..
AQ
11/12OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic ..
GL
11/12OPGEN INC : Results of Operations and Financial Condition, Financial Statements ..
AQ
11/11OPGEN : Reports Third Quarter 2020 Financial Results and Provides Business Updat..
AQ
More news
Financials (USD)
Sales 2020 4,12 M - -
Net income 2020 -24,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,16x
Yield 2020 -
Capitalization 39,5 M 39,5 M -
Capi. / Sales 2020 9,58x
Capi. / Sales 2021 3,53x
Nbr of Employees 39
Free-Float 99,9%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 5,33 $
Last Close Price 1,96 $
Spread / Highest target 188%
Spread / Average Target 172%
Spread / Lowest Target 155%
EPS Revisions
Managers
NameTitle
Oliver Schacht Chief Executive Officer & Director
Bill E. Rhodes Non-Executive Chairman
Johannes Bacher Chief Operating Officer
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
Vadim Sapiro Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPGEN, INC.73.45%40
LONZA GROUP AG56.17%44 950
MODERNA, INC.403.89%39 001
CELLTRION, INC.82.32%36 284
IQVIA HOLDINGS INC.11.32%32 977
SEAGEN INC.44.08%29 684